Andrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.
Andrew Zhu, MD, PhD
Advertisement
Articles by Andrew Zhu, MD, PhD
Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Advice on Decision Making for Frontline Treatment of HCCPublished: September 21st 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
